Precise. Effective. Safe.
The Problem
Mucus plugs are a core problem in COPD.
COPD affects 16 million in the US, 400 million globally, and is the third leading cause of death. 60% patients have a mucus plug disease subtype, where mucus accumulation leads to airway obstruction and irreversible lung damage. Current treatment options fail to address mucus plugs, leaving a critical gap in COPD patient care.
MucoLife Therapeutics has a solution to the problem.
Our Solution is Precise
MLT-001 is a modern mucolytic that dissolves accumulated mucus plugs from the lungs.
MLT-001 is an oligomer of natural amino acids that effectively removes calcium ions which are key mediators of mucus plugging in patients. MLT-001 is a first-in-class therapeutic approach that offers significant advantages over existing treatments, which have no or limited on mucus plugs and accumulated mucus.
Our Solution is Effective
MLT-001 has a unique mechanism of action that allows effective clearance of the airways.
Unlike current medications MLT-001 targets the root cause of COPD by detaching excess mucus. It significantly improves airflow and has the potential to slow or even halt disease progression.
In COPD patients, persistent mucus plugging leads to a decline in overall health, making it difficult to comply with treatment plans. MLT-001 overcomes these debilitating symptoms and has the potential to significantly improve the quality of life. MLT-001 shows promise as a valuable addition to the treatment landscape for COPD, with potential to expand into multiple other mucus-related lung diseases such as asthma, bronchiectasis, and cystic fibrosis.
Our Solution is Safe
MLT-001 offers a unique advantage by directly and locally targeting accumulated mucus in the airways.
Unlike existing treatments, MLT-001 does not act on airway cells hidden beneath the mucus, making it an ideal candidate for inhaled therapy. MLT-001 acts locally in the airways, minimizing the risk of unwanted side effects from systemic medications affecting the entire body. By directly addressing the source of the disease, the impact of MLT-001 goes beyond symptom relief.